Cipla inks pacts to invest in iCaltech Innovations

Published On 2025-07-22 10:32 GMT   |   Update On 2025-07-22 10:32 GMT
Advertisement

Mumbai: Cipla Limited has announced that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited, subject to completion of certain conditions.

iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care.

Commenting on the development, Mr. Achin Gupta, Global COO, Cipla Limited said, “As lung leaders, our decision to invest in iCaltech reflects Cipla's commitment to advancing respiratory diagnostics. With the aim to reduce the existing gap in the current ecosystem, our strategic funding will enable iCaltech to further expand and develop innovative devices. We remain committed towards providing easy access to high-quality diagnostic solutions across India.”

"Strategic partnerships remain central to Cipla’s innovation engine, as the company continues to expand its digital, devices and diagnostics offerings and build on its legacy of lung leadership," Cipla stated in a release.

Read also: Abbott India names Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy

iCaltech is a Bangalore based ISO 13485 certified Medical Devices Company. iCaltech conceptualises, develops, manufactures and markets Regulatory approved Medical Diagnostic Products. iCaltech conceptualises, develops, manufactures and markets Regulatory approved Medical Diagnostic Products. 

Advertisement

Read also: Cipla Gets CDSCO Panel Nod To BE Study, Phase III Trial of Semaglutide for Weight Management

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. The company strengths lies in the respiratory, anti-retroviral, urology, cardiology, antiinfective and CNS segments. Cipla 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News